CRISPR Therapeutics AG — Director's Dealing 2018

Jan 2, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2017-12-28

Reporting Person: Dylan-Hyde Tyler (Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-28	Common Shares	M	700	$14.43	Acquired	115904	Direct
2017-12-28	Common Shares	S	700	$21.75	Disposed	115204	Direct
2017-12-29	Common Shares	M	6230	$14.43	Acquired	121434	Direct
2017-12-29	Common Shares	S	6230	$21.75	Disposed	115204	Direct
2017-12-29	Common Shares	M	9070	$12.57	Acquired	124274	Direct
2017-12-29	Common Shares	S	1070	$21.75	Disposed	123204	Direct
2017-12-29	Common Shares	S	8000	$23.76	Disposed	115204	Direct
2017-12-29	Common Shares	S	15000	$22.68	Disposed	100204	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-28	Stock Option (Right to Buy)	$14.43	M	700	Disposed	2027-06-15	Common Shares (700)	Direct
2017-12-29	Stock Option (Right to Buy)	$14.43	M	6230	Disposed	2027-06-15	Common Shares (6230)	Direct
2017-12-29	Stock Option (Right to Buy)	$12.57	M	9070	Disposed	2026-07-15	Common Shares (9070)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.7606 to $23.90, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.6771 to $23.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F4: This option was granted on June 15, 2017 with respect to 65,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017.

F5: This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.